The parental AML14 human myeloid leukemic cell line was established from a 68-year-old man who presented with FAB M2 acute myeloid leukemia.
|Product Type:||Cell Line|
|Cell Type:||Hematopoietic-Myeloid Leukemia|
|Organism:||Homo sapiens, human|
|Morphology:||AML14: Undifferentiated, resembles immature myeloid precursors. Exhibits eosinophilic differentiation in suspension in response to IL-3, IL-5, and GM-CSF., AML14.3D10: Proliferates as an eosinophilic myelocyte to metamyelocyte, containing eosinophil secondary granules., AML14.eos: Proliferates as an eosinophilic myelocyte to metamyelocyte, containing eosinophil secondary granules.|
|Growth Conditions:||RPMI 1640, 8% FBS, 2mM L-glutamine, 1mM Sodium pyruvate, 50uM Beta-mercaptoethanol|
|Cryopreservation:||90% FBS + 10% DMSO|
|Comments:||AML14.3D10: When the density of 1x 106 cell/mL is exceeded, the cells appear to degranulate, which is fatal to the culture, presumably due to the toxic nature of eosinophil granule proteins. It is also difficult to resurrect the line from frozen aliquots for the same reason. Initial viability after thawing is usually about 20%‐30%. Recovery is facilitated by frequent replacement of culture medium during the first 72 h after thawing., AML14.eos: They exhibit adverse reactions to alkaline conditions and to serum with high iron content. If they start to revert to the parental strain they can be induced back to the eosinophilic mode with 100 pM GM-CSF, 250 pM IL-3 and 1 ng/mL IL-5.|
If you publish research with this product, please let us know so we can cite your paper.